Nigrostriatal overabundance of alpha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity by Gaugler, Meret Nora et al.
ORIGINAL PAPER
Nigrostriatal overabundance of a-synuclein leads to decreased
vesicle density and deficits in dopamine release that correlate
with reduced motor activity
Meret Nora Gaugler • Ozgur Genc • Wojciech Bobela • Safa Mohanna • Mustafa Taleb Ardah •
Omar Mukhtar El-Agnaf • Marco Cantoni • Jean-Charles Bensadoun • Ralf Schneggenburger •
Graham W. Knott • Patrick Aebischer • Bernard Laurent Schneider
Received: 19 August 2011 / Accepted: 14 February 2012 / Published online: 24 February 2012
 Springer-Verlag 2012
Abstract a-Synuclein (a-syn) is a presynaptic protein
present at most nerve terminals, but its function remains
largely unknown. The familial forms of Parkinson’s disease
associated with multiplications of the a-syn gene locus
indicate that overabundance of this protein might have a
detrimental effect on dopaminergic transmission. To inves-
tigate this hypothesis, we use adeno-associated viral (AAV)
vectors to overexpress human a-syn in the rat substantia
nigra. Moderate overexpression of either wild-type (WT)
or A30P a-syn differs in the motor phenotypes induced,
with only the WT form generating hemiparkinsonian
impairments. Wild-type a-syn causes a reduction of dopa-
mine release in the striatum that exceeds the loss of
dopaminergic neurons, axonal fibers, and the reduction in
total dopamine. At the ultrastructural level, the reduced
dopamine release corresponds to a decreased density of
dopaminergic vesicles and synaptic contacts in striatal ter-
minals. Interestingly, the membrane-binding-deficient A30P
mutant does neither notably reduce dopamine release nor it
cause ultrastructural changes in dopaminergic axons,
showing that a-syn’s membrane-binding properties are
critically involved in the presynaptic defects. To further
determine if the affinity of the protein for membranes
determines the extent of motor defects, we compare three
forms of a-syn in conditions leading to pronounced degen-
eration. While membrane-binding a-syns (wild-type and
A53T) induce severe motor impairments, an N-terminal
deleted form with attenuated affinity for membranes is
inefficient in inducing motor defects. Overall, these results
demonstrate that a-syn overabundance is detrimental to
dopamine neurotransmission at early stages of the degener-
ation of nigrostriatal dopaminergic axons.
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Introduction
The protein a-synuclein (a-syn) is mainly present in the
presynaptic compartment and is considered to exert
important functions in the control of neurotransmitter
release. Mounting evidence indicates a protective role for
a-syn at the synapse, where synuclein proteins have a non-
classical chaperone activity facilitating the assembly of the
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SNARE complex [6, 10]. Indeed, a-syn has been suggested
to participate in the regulation of neurotransmitter
homeostasis and release in the adult brain, in particular in
the dopaminergic neurons that are selectively vulnerable to
Parkinson’s disease (PD) [1, 2, 9, 34, 47, 57].
a-Synuclein is also linked with pathogenic roles in the
nervous system. Missense mutations in the a-syn gene are a
rare, but defined cause of PD [33, 43, 58] and the protein
constitutes the major component of Lewy bodies [50], the
histological hallmark of PD. Moreover, excess of the wild-
type (WT) protein leads to PD in families with a multi-
plication of the a-syn gene locus [11, 23, 49], and the
difference in clinical severity between duplication and
triplication families suggests a direct relation to gene
dosage. Interestingly, polymorphisms in the a-syn gene
possibly implicated in the expression level of the protein
have recently been linked with sporadic forms of the dis-
ease in genome-wide association studies [44, 48].
Therefore, it is conceivable that the intracellular accu-
mulation of a-syn can lead to functional perturbations in
neurotransmission, as part of the disease process. Recent
publications demonstrate that moderate WT a-syn over-
expression reduces the recycling vesicle pool at mouse
glutamatergic synapses and inhibits exocytosis in dopa-
mine neurons [39]. Functional deficits were further
explored in hippocampal neuronal cultures derived from a-
syn transgenic mice, revealing enlarged vesicles and evi-
dent deficits in neurotransmitter release [45]. At the
nigrostriatal level, transgenic mice expressing a truncated
form of a-syn show an age-dependent dysfunctional
redistribution of SNARE proteins in the striatum [18].
Defects in synaptic transmission and axonal transport were
reported in rats injected with an AAV2 vector encoding
a-syn A53T [12]. However, it remains largely unknown
what are the functional in vivo effects of overabundant a-
syn at nigrostriatal dopaminergic synapses and if impaired
neurotransmitter release contributes to the parkinsonian
motor phenotype. Here, we focus on the targeted overex-
pression of a-syn in the nigrostriatal projections of the rat,
a structure which displays selective vulnerability to a-syn
toxicity [21, 28, 35].
Our aim was to create a specific functional perturbation
in dopamine transmission using a viral gene-delivery
system that allows for the adjusted overexpression of a-
syn at levels causing only a minimal loss of dopaminergic
neurons. We show that overabundant a-syn diminishes
striatal dopamine release in the remaining neurons and
leads to impaired motor behavior. At the ultrastructural
level, a-syn causes a reduction in the density of presyn-
aptic vesicles in the striatal neuropil, concomitant with
indications of autophagic degeneration. By comparing the
WT and A53T forms of a-syn to lipid-binding deficient
variants [7, 26, 53], we demonstrate that these functional
defects depend on the interaction of a-syn with biological
membranes.
Materials and methods
Plasmid construction
Human WT and A30P a-syn cDNAs (GenBank accession
no. NM_000345) were inserted into the pAAV-pgk-MCS
backbone, modified from the serotype 2 pAAV-cmv-MCS
(Stratagene, La Jolla, CA, USA) using standard cloning
procedures. For the comparison between the WT, A53T and
D2-11 forms of a-syn, the cDNAs were inserted in the
pAAV-pgk-MCS-WPRE backbone, containing the Wood-
chuck hepatitis virus post-transcriptional regulatory
element (WPRE), using standard cloning procedures. The
following primers were used to amplify the D2-11 sequence
from the full-length a-syn cDNA: 50-ATGCATCGATA
CCATGAAGGAGGGAGTTGTGGCTGCT-30 and 50-AT
GGCAGATCTTTAGGCTTCAGGTTCGTAGTCTTGA-30.
Recombinant AAV2/6 production and titration
Recombinant pseudotyped rAAV2/6 were produced, puri-
fied and titrated as described before [14]. The titers
measured for AAV-pgk-a-syn-WT, AAV-pgk-a-syn-A30P
and AAV-pgk-GFP used were 8 9 1010 TU/ml (4.1 9
1013 vg/ml), 1 9 1011 TU/ml (1.7 9 1014 vg/ml) and
2.6 9 1010 TU/ml (1.7 9 1013 vg/ml), respectively. The
vectors AAV-pgk-a-synD2-11-WPRE, AAV-pgk-a-syn-
WT-WPRE, and AAV-pgk-a-syn A53T-WPRE had titers
of 1.3 9 1010 TU/ml (1.3 9 1014 vg/ml), 1.3 9 1010 TU/
ml (5.8 9 1013 vg/ml) and 6.4 9 109 TU/ml (1.3 9 1014
vg/ml), respectively.
Stereotaxic unilateral injection into the SNpc of rats
Female adult Sprague–Dawley rats (Charles River Labo-
ratories, France), weighing approximately 200 g were
housed in a 12-h light/dark cycle, with ad libitum access to
food and water, in accordance with Swiss legislation and
the European Community Council directive (86/609/EEC)
for the care and use of laboratory animals. Stereotaxic
injections of AAV vectors were performed as described
previously [14]. For complete lesion of the medial fore-
brain bundle (MFB), an adult female Sprague–Dawley rat
received a unilateral injection of 6-hydroxydopamine
(6-OHDA, Sigma, USA) at anterio-posterior –2.6 mm,
medio-lateral ?1.7 mm, dorso-ventral -8.55 mm, with an
injection speed of 1 ll/min. The concentration of 6-OHDA
was at 20 lg in 4 ll of ascorbic-saline.
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HPLC analysis of dopamine and dopamine metabolites
Contents of dopamine and metabolites were measured as
described before [14]. Results are expressed as a percent-
age of the non-injected hemisphere.
ELISA assays and western blot analysis for a-syn
Brain samples of substantia nigra (SN) and striatum of both
hemispheres were obtained from rats unilaterally injected in
the SN with a-syn vectors. These samples were homogenized
in CelLytic buffer, consisting of mild detergent, bicine and
150 mM NaCl (Sigma-Aldrich Company Ltd., Dorset, Eng-
land, Product Number: C3228), supplemented with a cocktail
of protease inhibitors, including AEBSF, aprotinin, E-64,
EDTA, and leupeptin (Calbiochem-Novabiochem Corpora-
tion, San Diego, CA), and centrifuged at 3,0009g for 30 min.
The supernatants were collected, total protein concentration
adjusted to 0.5 mg/ml, and then stored at -80C.
Human a-syn was measured using a sandwich ELISA as
described previously, with modifications to improve the
sensitivity for low quantities of a-syn in biological samples
[42]. A black 384-well ELISA plate (Nunc Maxisorb,
NUNC, Denmark) was coated overnight at 4C with 1 lg/ml
of a monoclonal antibody recognizing residues 121–125 of
human a-syn (AB 211, Santa Cruz Biotechnology, USA)
(50 ll/well) in 200 mM NaHCO3 at pH 9.6. For detection of
total a-syn, the plate was similarly coated with 1.25 lg/ml of
the monoclonal anti-a-syn antibody syn-1 (clone 42, BD
Transduction Laboratories, USA). The plate was washed
four times with PBST (0.05% Tween 20/PBS), and blocked
for 2 h at 37C with 100 ll PBS containing 2.5% gelatin
(fish skin gelatin 45%, Sigma, USA) and 0.05% Tween 20.
After four washes with PBST, 50 ll of brain lysate were
added to each well and incubated for 2 h at 37C. Captured
a-syn was detected by 0.2 lg/ml of a polyclonal anti-a-syn
antibody raised against recombinant full-length human a-syn
(FL-140, Santa Cruz Biotechnology; 50 ll/well), followed
by 50 ll of HRP-labeled goat anti-rabbit antibody in
blocking buffer (1:5,000; Jackson ImmunoResearch Labo-
ratories, West Grove, USA). Bound HRP activity was
assayed by 50 ll of enhanced chemiluminescent substrate
(SuperSignal ELISA Femto Maximum Sensitivity Substrate,
Pierce Biotechnology, Rockford, USA) per well, and relative
light units were measured on a Victor3 1420 microplate
reader (Wallac). A standard curve was established on wells
of 50 ll recombinant human a-syn solution at different
concentrations in blocking buffer. Recombinant human full-
length a-syn was expressed in Escherichia coli and purified
as described previously [25, 42]. Intra-assay and inter-assay
coefficients of variation were\10%.
SDS-PAGE and immunoblotting: brain lysates were
boiled in the sample loading buffer (250 mM TrisHCl
pH 6.8, 10% SDS, 30% glycerol, 5% b-mercaptoethanol,
0.02% bromophenol blue) for 10 min. Samples (25 lg/
lane) were then separated on 15% SDS-PAGE, 1 mm-thick
gels. The separated proteins were transferred to nitrocel-
lulose membranes (0.45 lm; Whatman GmbH-Germany)
at 90 V for 45 min. The membranes were boiled for 5 min
in PBS, and then blocked with 5% marvel dried skimmed
milk/PBS-Tween-20TM (0.05%; PBST) for 1 h. The
membranes were probed overnight at 4C with the fol-
lowing primary antibodies: syn211 mouse monoclonal
antibody to human a-syn (a.a. 121–125); or FL-140 rabbit
polyclonal antibody, which recognizes human and rat
a-syn (Santa Cruz Biotechnology). The membranes were
washed several times with PBST, followed by incubation
with HRP-conjugated goat anti-rabbit (Dako Ltd., Ely,
UK), or goat anti-mouse (Dako Ltd.) as appropriate, for
60 min. The protein bands were visualized by using
ECL reagents (Pierce, Rockford, IL) as described by the
manufacturer.
Behavioral analysis
Cylinder test, amphetamine-induced rotation (D-amphet-
amine sulphate: 2.5 mg/kg i.p., Sigma, St Louis, MO,
USA), and apomorphine-induced rotation (apomorphine–
HCl: 0.1 mg/kg s.c., Sigma) were performed as described
previously [14], before virus injection and at monthly
intervals post-surgery. In the cylinder test, only the mea-
surements with a minimum of 16 touches were included in
the analysis.
Immunohistological analyses and counting
The rats were killed and tissue processed as described
before [4]. For immunofluorescence, slices were washed
in PBS, blocked in 10% normal donkey serum (NDS)
(Jackson ImmunoResearch, Suffolk, UK) and 0.1% Triton
X-100 in PBS for 2 h at room temperature, incubated
overnight at 4C with an anti-a-syn antibody (sheep IgG,
1:800; AB5334P Chemicon) in blocking solution, and for
2 h at room temperature with a secondary antibody con-
jugated to a 488-Alexa Fluor dye (Molecular Probes,
Invitrogen AG, Basel, Switzerland). They were washed and
mounted on glass slides using MOWIOL medium.
Stereological estimates of Nissl-positive nigral neurons
were obtained as described previously [15]. For bright-
field microscopy analyses, the slices were treated, and
the percentage of immunoreactive neurons and striatal
dopaminergic innervation determined as described previ-
ously [4, 14]. Primary antibodies used were anti-tyrosine
hydroxylase (TH) (rabbit IgG, 1:500; AB152 Chemicon)
and anti-vesicular monoamine transporter 2 (VMAT2)
(rabbit IgG, 1:2,000; AB1767 Chemicon).
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Amperometry
Amperometric measurements of dopamine release in
striatal slices followed previously described methods
[29, 37]. Coronal forebrain slices (200 lm thickness) on
the level of the striatum were cut with a vibratome (Leica
VT1000S, Leica Microsystems, Germany), using the rats
9 weeks after unilateral injection of either the WT, or
A30P a-syn construct. The coronal slices were severed at
the midline and incubated for 1 h at 36C in a solution
composed of 125 mM NaCl, 25 mM NaHCO3, 2.5 mM
KCl, 1.25 mM NaH2PO4, 1 mM MgCl2, 2 mM CaCl2,
and 25 mM glucose at pH 7.4, bubbled with 95% O2 and
5% CO2. During recordings, the same solution at room
temperature (21–23C) was used as extracellular
solution.
For amperometry, we used commercially available car-
bon fiber electrodes of 5 lm diameter (ALA Scientific
Instruments, USA), insulated to the tip. On the day of
recording, their tips were cut off to guarantee a fresh
detection surface. We puff-applied a bath solution con-
taining 10 mM dopamine against the electrodes. Only
electrodes which responded with currents of at least 500 pA
(usually, 1–2 nA) were used for subsequent amperometry.
The carbon fiber was inserted into the dorsomedial striatum
at the level of its largest area extent at a depth of *50 lm
from slice surface. To evoke dopamine release, the
slices were perfused with a high K? solution, containing
70 mM KCl, 57.5 mM NaCl, 25 mM NaHCO3, 1.25 mM
NaH2PO4, 1 mM MgCl2, 2 mM CaCl2, and 25 mM glu-
cose. Current signals were recorded with a patch-clamp
amplifier (EPC9/2; HEKA Elektronik, Lambrecht, Ger-
many) at a detection potential of ?800 mV, and digitized at
a sampling rate 20 kHz using the Patchmaster software
(HEKA). Measurements were performed in at least n = 4
pairs of slices from each injected rat, using the non-injected
and injected hemispheres selected at random. In this
way, we obtained paired comparisons of amperometric
current traces from the injected, and non-injected side for
each rat. The experimenter was blinded to the injected
construct. Current amplitudes were measured off-line
using the IGOR Pro 6 software (Wavemetrics Inc., Portland,
OR, USA).
Electron microscopy
Resin-embedded brain tissue was prepared for serial
imaging in the focused ion beam scanning electron
microscope using a protocol previously described [31],
with the difference that deeply anesthetized rats were
directly perfused with 2.5% glutaraldehyde and 2% para-
formaldehyde in 0.1 M phosphate buffer at pH 7.4, and
sections from fixed brains were vibratome sectioned at the
level of the largest striatal surface, heavy-metal stained,
dehydrated, and resin embedded.
From the resin-embedded sections, the region to be
imaged was selected under a light microscope, mounted
onto a blank resin block, and trimmed with an ultrami-
crotome, before being placed in a Zeiss NVision 40 FIB/
SEM microscope. The block face was imaged with an
electron beam set at 1.4 keV. Pixel dwell time was
*10 ls, and the total image size was 2,048 9 1,536 pix-
els. Block face milling was carried out with a gallium ion
source of current of 30 pA with a voltage of 30 keV.
Milling depth was between 10 and 20 nm, but measured
after each imaging session using the cylindrical size of the
mitochondria as a Ref. [16]. Image analysis was carried out
using the Neurolucida confocal module for serial images
(Microbrightfield, USA). In all image series the voxel size
and contrast levels showed all membranous structures, and
these were always visible in 3D. This ensured that synapses
and vesicles could be counted as an absolute value within
each volume without using any stereological estimation.
Statistical analysis
Data are expressed as average ± standard error of the
mean. Statistical analysis was performed using the Statis-
tica software (StatSoft Inc., OK, USA). Level of
significance was set at 0.05. Applied specific tests are
indicated in the figure legends.
Results
Moderate nigrostriatal expression of human WT a-syn
impairs motor behavior
For a-syn expression, AAV vectors pseudotyped with a
serotype 6 capsid were chosen because of their high tro-
pism for nigral dopaminergic neurons [4, 14]. We injected
each vector unilaterally into the SN of cohorts of adult
Sprague–Dawley rats at a virus dose of 2.8 9 107 trans-
ducing units (TUs), which had previously been
demonstrated to cause only minimal and non-specific loss
of dopaminergic neurons in this brain area [14]. To
determine whether WT a-syn and its lipid-binding deficient
A30P mutant are able to affect motor behavior in a regimen
of mild unilateral a-syn overexpression, we used several
tests to detect possible motor asymmetries. When animals
were injected with the WT form of a-syn, we observed
motor asymmetries in both spontaneous behavior and drug-
induced rotational behavior, which developed progres-
sively over a period of 4 months following virus injection
(Fig. 1). In the cylinder test, animals with nigrostriatal
overexpression of WT a-syn showed a significantly
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reduced use of the forepaw contralateral to the injected
hemisphere, reaching 33 ± 5% of total touches at
3 months post-injection (Fig. 1a). In the same animals, we
observed the emergence of apomorphine-induced rotations
(Fig. 1b), a behavioral effect that mainly corresponds to a
postsynaptic sensitization of dopamine receptors. In con-
trast, animals overexpressing A30P a-syn remained at
baseline values for the entire length of the experiment in
both tests (Fig. 1b, c). In amphetamine-induced motor
behavior, neither WT nor A30P a-syn caused a clear
rotational phenotype (average rotation rates B1.5 turns/
min; Fig. 1c). However, due to opposite trends of the
rotations we noticed a significant difference between both
groups, which might reflect subtle changes in dopamine
distribution.
Comparing WT a-syn and GFP vectors at the same dose
of 2.8 9 107 TUs showed that the GFP vector did not
cause any significant behavioral changes (Fig. 1d–f).
In addition, we investigated whether the strength of the
behavioral deficits depends on a-syn expression level. The
comparison between 1.4 9 107 TUs (low dose) and
2.8 9 107 TUs (high dose) of the WT-a-syn coding vector
showed a dose dependence of the effects of WT a-syn on
spontaneous behavior, with only the higher viral load dis-
playing significant motor impairments (Fig. 1d). Animals
overexpressing WT a-syn also developed apomorphine-
induced rotations, most apparent at 3 months (Fig. 1e).
Again, we did not observe any significant rotational
behavior in response to amphetamine (Fig. 1f). The
dependence of behavioral impairments on vector dose is
likely to reflect differences in the obtained striatal level of
human a-syn. Indeed, at 5 weeks post-injection, we com-
pared the level of a-syn in the striatum between the high
(n = 4) and low vector (n = 5) doses using an ELISA
assay for human a-syn. The average human a-syn level
in the high vector dose group was increased on average
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Fig. 1 WT a-syn induces changes in spontaneous and drug-induced
behavior over time. Motor asymmetries in rats injected with
2.8 9 107 TUs of AAV-pgk-a-syn-WT (n = 18) and AAV-pgk-
a-syn-A30P (n = 20): a cylinder test, b apomorphine-induced
rotametry, and c amphetamine-induced rotametry. Two-way repeated
measure ANOVA with Newman-Keuls post hoc test: for (a) group
effect, F(1,36) = 6.59, p \ 0.05; for (b) group 9 time, F(4,144) =
14.62, with p \ 0.001 at 5 weeks; for (c) group effect, F(1,36) =
16.14, p \ 0.001. Changes in spontaneous and drug-induced behavior
depending on virus dose and comparison to a control GFP vector.
Rats for each condition were injected with either the AAV-pgk-a-syn-
WT at a dose of 1.4 9 107 (n = 10) or 2.8 9 107 TUs of (n = 10),
or with the AAV-pgk-GFP vector (n = 10) at a dose of 2.8 9 107
TUs. Motor asymmetry was measured using d the cylinder test,
e apomorphine-induced rotametry, and f amphetamine-induced rota-
metry. Two-way repeated measure ANOVA with Newman-Keuls
post hoc test for (d) group 9 time, F(2,25) = 1.73, *p \ 0.05 versus
pre-test and GFP group; for (e) group 9 time, F(2,27) = 5.4, with
#p \ 0.05 versus pre-test and p = 0.07 versus GFP group and
*p \ 0.05 versus pre-test and GFP group
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*1.7-fold when compared with the low dose, although this
difference did not reach statistical significance (data not
shown).
To explore the cause of the motor behavior, we analyzed
histopathological alterations of dopaminergic markers in
the nigrostriatal system.
WT a-syn induces a moderate but more acute loss
of dopaminergic markers than the A30P mutant
We next assessed the consequences of a-syn overexpression
on the loss of dopaminergic neurons in the SN pars compacta
(SNpc) and dopaminergic fiber density in the striatum.
Following injection of the a-syn viral vectors, the
recombinant human a-syn protein was well detected in
vivo by immunohistochemistry in the SN and the striatum
(Fig. 2a, b). We also verified quantitatively that both forms
of the protein presented a similar distribution and compa-
rable protein levels between the SN and the striatum. In a
separate cohort of animals, we measured expression levels
3 weeks after virus injection using an ELISA assay for
human a-syn. With an equivalent viral load (1.4 9 107
TUs), human a-syn content was comparable between the
WT and A30P constructs both in the SN (170 ± 49 and
176 ± 108 ng human a-syn/mg of total protein for WT
(n = 5) and A30P (n = 5), respectively) and striatum
(156 ± 46 and 154 ± 88 ng, respectively). This result was
further confirmed by western blotting of striatal protein
extracts revealing a specific 16 kDa band in striatal protein
extracts derived from the injected hemisphere with the
human specific syn211 antibody (Fig. 2c). Using an ELISA
assay detecting both rat and human a-syn, we found a
2.5 ± 0.4 (WT, n = 5) and 2.2 ± 0.2 (A30P, n = 5) fold
increase in the total a-syn level in the injected striatum, as
compared with the non-injected hemisphere. There was no
significant difference between both forms of a-syn in the
level of overexpression.
We assessed the effect of a-syn expression on nigral
neurons and striatal projections for the viral doses at which
we observed differential motor disturbances (Fig. 2d–h).
WT-a-syn and A30P-a-syn viruses were injected at either
1.4 9 107 (low dose) or 2.8 9 107 TUs (high dose).
At 3 months post-injection, overexpression of WT a-syn
led to a significant loss of neurons positive for VMAT2 in
the SNpc (33 ± 4.9 and 35 ± 6.9%, for respective doses)
(Fig. 2d, e). Quantification of Nissl-positive neurons in the
SNpc revealed a 26.5 ± 4.6% reduction versus the non-
injected side in the group injected with the highest dose of
the WT-a-syn coding vector, confirming that the neurons
had indeed degenerated. In contrast, neuron numbers
remained largely unchanged for A30P a-syn (4.0 ± 3.1
and 5.5 ± 2.1% reduction for respective doses) (Fig. 2d,
e). For comparison, an injected dose of 2.8 9 107 TUs of
an AAV vector encoding GFP led to a loss of VMAT2-
positive neurons significantly lower than WT a-syn, con-
firming the specific toxicity of human a-syn (Fig. 2e).
We next examined the relative marker loss induced by
the two forms of a-syn in the SN’s projection area. Mea-
suring the density of VMAT2 immunoreactivity in the
striatum, we found a decrease of 24.3 ± 6.1% (low dose)
and 25.1 ± 4.9% (high dose) for WT a-syn, and
15 ± 2.6% (low dose) and 8.2 ± 2.6% (high dose) for the
A30P mutant (Fig. 2d, f). In addition, to confirm the a-syn-
induced changes with a second dopaminergic marker, both
analyses were repeated with TH immunohistochemistry
(Fig. 2g, h). The measures obtained were comparable
between VMAT2 and TH, except for the case of A30P, for
which the VMAT2 density was slightly more reduced than
TH density (Fig. 2f, h).
Overall, the histological analysis shows that the WT
form of a-syn causes significantly higher marker loss as
compared to the A30P mutant. However, the overall level
of degeneration even with WT a-syn (25–35%) does not
provide a reasonable explanation for the observed func-
tional impairment. Therefore, we set out to explore
functional defects in the dopaminergic nigrostriatal pro-
jections that might explain the motor symptoms in the
absence of overt degeneration of dopaminergic fibers.
Amperometric measurements reveal impaired evoked
dopamine release following WT a-syn overexpression
To explain the observed deficits in motor behavior, we next
measured dopamine release in the striatum with carbon
fiber amperometry [37, 54]. Since WT a-syn, but not the
A30P mutant induced motor deficits (Fig. 1), we compared
the two forms of a-syn, considering the A30P mutant as a
control form of a-syn with a loss of membrane-binding
capacities [10, 39]. In order to minimize cell loss, all
subsequent experiments were conducted with the lower
dose of a-syn-expressing vectors (1.4 9 107 TUs).
For animals overexpressing WT a-syn, we found a
significant reduction of amperometric signals in the injec-
ted relative to the non-injected hemisphere (Fig. 3). In the
example of Fig. 3a, high K? caused an amperometric
current response of *20 pA in slices from the non-injected
hemisphere (Fig. 3a, black traces), whereas the responses
were reproducibly smaller in the striata of the injected
hemisphere (Fig. 3a, red traces). In contrast, striata over-
expressing A30P a-syn had comparable amperometric
responses for the non-injected, and the injected hemi-
spheres (Fig. 3b, black and red traces, respectively). On
average, amperometric responses were significantly
reduced with WT a-syn (from 36.4 ± 6.4 to 19.7 ± 8.1
pA, or a reduction by 51.1%; p \ 0.01), whereas the rel-
ative reduction was not significant for the A30P form of
658 Acta Neuropathol (2012) 123:653–669
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a-syn (12.1 ± 3.3%; Fig. 3c). These results demonstrate
that mild overexpression of a-syn causes a strong reduction
of dopamine release that is specific to WT a-syn and cor-
relates with the observed deficit in spontaneous behavior.
Striatal content of dopamine and dopamine metabolites
is reduced to a similar extent in WT and A30P a-syn
overexpressing animals
To determine whether reduced synthesis of dopamine or
altered dopamine metabolism contributes to the observed
dopamine release deficiency, we measured striatal levels of
transmitter and metabolites in animals injected with
1.4 9 107 TUs of vector at 8 weeks post-injection. Overall,
dopamine content was reduced in the injected hemisphere for
both WT and A30P mutant a-syn (to 77 ± 9% and 81 ± 2%
of the non-injected hemisphere, respectively), while the
decrease in levels of the metabolites DOPAC and HVA were
overall less pronounced (Fig. 3d). The observed reduction in
striatal dopamine levels was not specific to the WT protein and
appeared to be in the same range as the observed dopaminergic
marker loss for a-syn WT (see above, Fig. 2d–g). We did not
measure any significant change in the striatal concentration of
serotonin (5-HT; Fig. 3d).
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Fig. 2 WT a-syn induces higher loss of dopaminergic markers than
A30P a-syn, while both forms of the protein show similar transgene
expression in the SN and striatum. The animals were injected either with a
high (2.8 9 107 TUs) or with a low dose (1.4 9 107 TUs) of vector.
Expression of A30P (a) and wild-type a-syn (b) in the SN (lower panel)
and striatum (upper panel) of rats administered with high dose of an AAV
vector as revealed by a-syn immunostaining at 4 months post-injection.
Scale bars: 1 mm. c Western blot analysis of striatal proteins at 3 weeks
post-injection (low dose), comparing three A30P-injected, three a-syn
WT-injected and two non-injected (NI) hemispheres. Antibodies were
used to detect human (Syn211) or total a-syn (FL-140). Note the modest
increase in the level of total a-syn in transduced striata. d Photomicro-
graphs showing the loss of VMAT2-positive neurons and striatal fiber
density of animals injected with low vector dose. The injected
hemisphere is marked with an asterisk. e Loss of VMAT2-positive
neurons in the SNpc of animals injected with AAV-pgk-a-syn-A30P
(low dose, n = 9; high dose, n = 10), AAV-pgk-a-syn-WT (low and
high dose, n = 10), and AAV-pgk-GFP (n = 10). f Decrease of
VMAT2-positive striatal fiber density (A30P low and high dose: n = 8
and 9; a-syn-WT: n = 10 for both conditions; GFP: n = 8). Animals
injected with the low dose of the a-syn-WT or A30P vectors (n = 10 in
each group) were also analyzed for the following parameters: g loss of
TH-positive neurons in the SNpc, h decrease of TH-positive striatal fiber
density. All results are expressed as a percentage of the non-injected side.
The histological analysis of the nigrostriatal system was performed
4 months post-vector injection. Comparisons were done by one-way
ANOVA, followed by Newman-Keuls post hoc test (e, f) or two-tailed
Student t-test (e–h); *p \ 0.05 versus the GFP and A30P groups (one-
way ANOVA); **p \ 0.01 and ***p \ 0.001 versus the A30P group
(Student t-test)
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Ultrastructural three-dimensional imaging of striatal
neuropil and morphological identification
of dopaminergic axons
In order to investigate possible presynaptic correlates of the
reduced dopamine release, we studied the effect of a-syn
on the ultrastructure of dopaminergic axons in the nigro-
striatal system. We used a combined focused ion beam and
scanning electron microscope (FIB/SEM) [31] to serially
image at least two independent subvolumes in each con-
dition, accounting for a total volume of 6,110 lm3 of
neuropil for WT a-syn, 1,240 lm3 for A30P a-syn, and
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Fig. 3 Amperometric measurements show a reduction of evoked
dopamine release in striata overexpressing WT a-syn. a, b Represen-
tative traces of evoked current (with basal currents subtracted for
individual curves) and plot of maximum amplitudes of all slice pairs
for non-injected and injected hemispheres of individual rats admin-
istered with 1.4 9 107 TUs of AAV-pgk-a-syn-WT (a) or AAV-pgk-
a-syn-A30P (b). Across all measurements, the difference between
injected and non-injected hemispheres was significantly different
between WT-a-syn (n = 19) and A30P-a-syn (n = 17) overexpress-
ing animals (two-way repeated measures ANOVA, followed by
Tukey post hoc test, group effect: p \ 0.05). c Averages and
distributions of maximum amplitudes of evoked current in the
injected and non-injected hemispheres of animals overexpressing WT
(n = 4) or A30P a-syn (n = 4). **p \ 0.01 versus the non-injected
hemisphere (two-way repeated measure ANOVA, followed by a
Tukey post hoc test). d Striatal depletion of neurotransmitters and
metabolites in the striatum. Total content of dopamine (DA), DOPAC,
HVA and 5-HT in the striata of animals killed at 8 weeks after
injection with 1.4 9 107 TUs of virus (AAV-pgk-a-syn-WT, n = 6;
AAV-pgk-a-syn-A30P, n = 3). Results are expressed as the percent-
age of remaining dopamine, DOPAC, HVA or 5-HT in the injected
versus the non-injected hemisphere. *p \ 0.05 and #p = 0.06 (paired
Student t-test)
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2,280 lm3 for non-injected control striatal tissue. Each
series contained between 400 and 1,000 images with a
spacing of 8–15 nm (z spacing). With these datasets,
dopaminergic axons could be identified and reconstructed
in 3D.
Axonal projections within the striatal neuropil were
classified by synapse type and vesicle morphology. Up to
92% of all synapses in the rat neostriatum are asymmetrical
[24], corresponding for the greatest part to corticostriatal
and thalamostriatal glutamatergic excitatory afferents, and
to a smaller degree to a subgroup of striatal cholinergic
collaterals. We identified glutamatergic synapses by
asymmetrical contacts with prominently thickened post-
synaptic varicosities (Fig. 4a, open arrowheads).
In some cases, glutamatergic synapses appeared to be in
close proximity to synaptic contacts made on the same
dendritic spines by a second class of axons with a distinct
morphology (Fig. 4a, closed arrowhead). These synapses
contained large, pleomorphic, mainly flattened vesicles
with a lower contrast between vesicle membrane and
lumen, as described before in immunolabeled dopaminergic
terminals [17]. Vesicles were evenly distributed throughout
the whole axonal length, with only small clusters at iden-
tifiable synapses (see below, Fig. 5a). These axons appeared
highly homogenous and formed small en passant symmet-
rical synapses with dendritic spines and shafts (Fig. 4a,
closed arrowheads), a previously reported ultrastruc-
tural feature of dopaminergic fibers [22]. Therefore, the
morphology of this class of axons matched previously
described attributes of dopaminergic terminals in the rat
neostriatum.
We noticed two remaining axon subclasses that formed
symmetrical synapses and were mainly classified according
to the size and shape of their presynaptic vesicles. For each
axon type, the diameters of individual vesicles were mea-
sured to illustrate differences in shape and size (Fig. 4b).
GABAergic synapses were readily identifiable in our
samples, with very broad synaptic contacts [5] and small-
sized, round vesicles (Fig. 4b). Finally, a subpopulation of
axons, referred to as type-x, was distinguished by relatively
broad symmetrical synaptic contacts and large, mainly
round vesicles (Fig. 4b) with a dense vesicle membrane
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Fig. 4 Morphological identification of dopaminergic axons. a Two
representative series of consecutive images showing a glutamatergic
axon (open star) forming an asymmetric synaptic contact (open
arrowhead) on a dendrite. This synapse is closely juxtaposed to a
dopaminergic axon (closed star) forming a symmetric synaptic
contact (closed arrowhead). Scale bar: 500 nm. b For each type of
axon identified in a non-injected rat striatum, we measured the small
and large diameters of 50 individual vesicles present in axons and
synaptic terminals. The diameters of vesicles were measured in the
focal plane of the largest visible vesicle surface. Average diameter
values are indicated for each axon type. Glut indicates glutamatergic
vesicles. c Proportion of each synapse type, expressed as a percentage
of total synapses in four control non-injected striatal samples (black
bars). Note the complete elimination of synapses identified as
dopaminergic in the striatum sub-volume of a 6-OHDA-lesioned
animal (gray bars)
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strongly contrasting an electron-lucent lumen (not shown).
This class, as yet non-identified, appeared heterogeneous
and might comprise multiple subtypes such as cholinergic
or serotoninergic terminals. Supplementary movie 1 gives a
representative sample of aligned FIB/SEM images of the
rat striatal tissue, with identified synapse types.
To definitively demonstrate the nature of the dopaminergic
axons identified by morphology, we repeated the same
imaging procedure on the striatum of a rat whose medial
forebrain bundle (MFB) had been lesioned with an injection of
6-OHDA, 3 weeks before analysis. Measuring the relative
percentages of the four synapse types in the depleted striatum,
we could no longer find the type of synapses we previously
identified as dopaminergic (16 ± 1.2% and 0%, for control
and 6-OHDA-lesioned striatum, respectively; Fig. 4c). Con-
versely, there was a relative increase in GABAergic and
glutamatergic synapses in the 6-OHDA-lesioned striatum
(Fig. 4c). Altogether, we conclude that morphological criteria
allow for the identification of dopaminergic axons in FIB/
SEM images.
Quantitative ultrastructural analysis reveals a depletion
of dopaminergic vesicles upon overexpression
of WT a-syn
Using the FIB/SEM analysis, we are now in a position to
quantify ultrastructural changes in 3D reconstructed
dopaminergic axons overexpressing human a-syn. We
analyzed striata of two rats per group, each injected with
1.4 9 107 TUs of WT-a-syn or A30P-a-syn virus at
10 weeks post-surgery. We determined vesicle density
within 3D-reconstructed dopaminergic axons in striatal
tissue (Fig. 5a). As we found dopaminergic vesicles widely
distributed throughout neurites, we measured total numbers
of axonal vesicles rather than vesicles situated around
synaptic active zones.
Total vesicle counts were normalized either to axon
volume (from which the volumes of mitochondria were
subtracted) (Fig. 5b), or axon length (Fig. 5c). In animals
with a nigrostriatal overexpression of WT a-syn, the
vesicle density was significantly reduced on the injected
hemisphere. The number of vesicles in dopaminergic
axons was diminished by 37 ± 0.1% when normalized to
axon length, and by 40 ± 0.1% when normalized to axon
volume, as compared to the vesicle density in the non-
injected hemispheres (Fig. 5b, c). In contrast, A30P-a-
syn did not reduce the density of dopaminergic vesicles
(Fig. 5b, c). In addition, the size of dopaminergic vesi-
cles was significantly increased in the hemisphere
expressing WT a-syn, as compared to the non-injected
contralateral side. Measuring 50 vesicles across four
axons per condition, the average large/small vesicle
diameters were 67.4 ± 0.4/40.7 ± 0.3 nm in the WT-a-
syn hemispheres, as compared to 54.9 ± 2.0/33.9 ±
1.5 nm in the control non-injected side (Student t-test,
p \ 0.005).
100
75
50
25
0
Ve
si
cl
es
 / 
ax
on
 vo
lu
m
e
injected
α-syn A30P
A30Pα-syn
non-injected
**
**
100
75
50
25
0Ve
si
cl
es
 / 
ax
on
 le
ng
th
 (µ
m)
Non-injected
α-syn
b
c
a
1µm
Fig. 5 The overexpression of
WT a-syn induces a depletion
of vesicles in dopaminergic
axons. a Representative 3D
reconstructions of dopaminergic
axons in random volumes
(4 9 4 9 4 lm), with
individual vesicles (red dots)
and mitochondria, for a non-
injected and a WT-a-syn
overexpressing hemisphere.
b, c Vesicle density in
dopaminergic axons from
injected and non-injected
hemispheres of WT-a-syn
overexpressing animals,
normalized to either axon
volume (b), or axon length (c).
WT a-syn: n = 21 injected,
n = 20 non-injected axons;
A30P: n = 19 injected, n = 24
non-injected axons. Student
t test: **p \ 0.01
662 Acta Neuropathol (2012) 123:653–669
123
These results indicate a clear reduction in the density of
vesicles in dopaminergic axons following overexpression
of human a-syn. The depletion of dopaminergic vesicles
could underlie the impaired striatal dopamine release
which we found in amperometric recordings.
WT a-syn reduces the number of dopaminergic
synapses and leads to the accumulation of autophagic
structures in dopaminergic axons
In order to further assess possible ultrastructural changes
that may explain the reduced dopamine neurotransmission,
we quantified the abundance of synapses in dopaminergic
axons. For each individual dopaminergic axon identified in
random striatal subvolumes, we determined the number of
synaptic contacts as defined by the presence of at least
three vesicles clustered in close proximity to juxtaposed
membranes (Fig. 6a). When compared to the non-injected
hemispheres, we found a 34% reduction in the number of
dopaminergic synapses, normalized to axon length, in
striata injected with the WT-a-syn virus. The A30P-mutant
did not show any effect (Fig. 6a).
Ultrastructural examination of striatal tissue also
revealed signs of distal degeneration confined to dopami-
nergic axons in hemispheres overexpressing WT a-syn.
Degenerating structures were composed of double- or tri-
ple-limiting membranes separated by an electron-lucent
lumen or single-membrane wrapped mitochondria at early
stages of demise (Fig. 6b). These features correspond
to earlier descriptions of autophagosomes [13, 40]. The
number of autophagic structures per axon length was
determined in 84 individual dopaminergic axons (with an
average length of 4.2 lm) from random striatal subvolumes
of four non-injected, two WT-a-syn and two A30P-a-syn
hemispheres, all at 10 weeks post-injection. Compared to
both non-injected and A30P samples, we found approxi-
mately six times as many degenerating structures in animals
overexpressing WT a-syn (Fig. 6c).
These results further indicated ultrastructural changes in
dopaminergic axons that are concomitant with early signs
of neurodegeneration, which might contribute to the
reduced dopamine release observed in amperometric
recordings.
Correlation of impaired dopaminergic motor function
with a-syn association to biological membranes
We found above that the A30P a-syn mutant, which is
deficient for binding biological membranes [7, 26], does
not cause motor impairments (Fig. 2) nor reduced dopa-
mine release (Fig. 1), and fails to significantly reduce
vesicle density in dopaminergic terminals (Fig. 5). We
sought to determine if other forms of a-syn would impact
motor behavior as a function of their ability to bind
membranes. Therefore, we compared WT a-syn to the
A53T mutant, which displays similar membrane-binding
properties as the WT form. In parallel, we expressed a-syn
D2-11, a N-terminal deletion mutant in which the a-helix
formation critical for membrane association is destabilized
[53]. To induce more pronounced degenerative effects, we
used AAV vectors with a modified expression cassette
designed for enhanced a-syn expression (see ‘‘Materials
and methods’’). This expression cassette was shown by
western blotting to express approximately 3.6-fold more
human a-syn than the previous vector following infection
of HEK293T cells. In addition, we measured by ELISA a
*eight-fold increase on average in the level of human
a-syn in the rat SN as compared with an identical dose
(1.4 9 107 TUs) of the previous vector, at 5 weeks post-
injection (data not shown).
***
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
Au
to
ph
ag
os
om
es
 / 
µm
 a
xo
n
α-synnon-inj A30P
#
0 
0.002 
0.004 
non-inj α-syn A30P
Sy
na
ps
es
 / 
ax
on
 le
ng
th
 (µ
m)
c
b
a
Fig. 6 The overexpression of WT a-syn in dopaminergic axons
induces a decrease in synapse numbers and an accumulation of
autophagic structures. a Synapse density in dopaminergic axons from
either non-injected (n = 42), WT (n = 20) or A30P a-syn (n = 19)
overexpressing hemispheres, normalized to axon length (lm). One-
way ANOVA, F(2,78) = 3.0, Newman–Keuls post hoc: #p = 0.05
versus non-injected control and p \ 0.05 versus A30P. b, c Auto-
phagosomes accumulate in dopaminergic axons of animals expressing
WT a-syn. The density of autophagic structures per lm of axon (c) is
significantly increased in response to WT a-syn (n = 21), as
compared to the non-injected controls (n = 47) and A30P mutant
(n = 20). Scale bar: 250 nm; Kruskal–Wallis test and bilateral
comparison, H(2, n = 88) = 25.3: ***p \ 0.01 compared to the non-
injected control group and p \ 0.001 compared to A30P mutant
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We first infected HeLa cells with AAV vectors encoding
a-syn (5 9 105 TUs for 2.5 9 104 cells) to assess the
intracellular distribution of the WT and D2-11 forms of
human a-syn. Immunodetection of a-syn (LB509 antibody)
revealed a punctate staining for a-syn, contrasting with the
diffuse cellular distribution of the D2-11 mutant (data not
shown), consistent with the previous observation that the
deletion of the amino acids 2-11 affects the ability of
human a–syn to associate with biological membranes [53].
Next, we tested WT a-syn, as well as the A53T and D2-
11 mutants for their ability to induce impairments in
spontaneous motor behavior. The vectors were injected at a
total dose of 1.25 9 107 TUs in the SNpc. The A53T
mutant led to impaired spontaneous forepaw activity to an
extent similar to WT a-syn, reaching 20.8 ± 3.3% and
24.6 ± 2.1% of contralateral paw touches 4 months post-
injection, respectively (Fig. 7a). Strikingly, a-syn D2-11
failed to produce significant motor asymmetry, with
49.7 ± 1.6% of contralateral forepaw activity. This result
was further confirmed in apomorphine-induced rotational
behavior. At 4 months, both the WT and A53T forms of
a-syn led to contraversive rotations (Fig. 7b), similar to the
previous experiment (see Fig. 2). In contrast, a-syn D2-11
did not produce significant rotational behavior up to
4 months post-injection. Amphetamine did not induce any
significant rotational behavior with any of the three a-syn
forms (data not shown).
Histological analysis revealed a similar loss of nigral
neurons as quantified by stereological counts of the
dopaminergic marker TH (WT a-syn: 60.3 ± 4.5%;
A53T: 61.8 ± 5.6%; Fig. 7c, e). Interestingly, the extent
of nigral neuron loss was significantly lower with the
D2-11 variant (26.6 ± 6.2%; p \ 0.001), although the
protein also displayed some toxic effects in these condi-
tions. In the striatum, the decrease in TH immunoreactivity
reached 46.6 ± 5.0% and 50.5 ± 5.9% in the groups
injected with the WT a-syn and A53T vectors, respec-
tively (Fig. 7d, f). Although a-syn D2-11 caused, on
average, a milder loss of TH-positive fibers (28.6 ± 8.6%),
the difference did not reach significance (p = 0.07).
Interestingly, immunostaining for human a-syn (LB509
antibody) in the striatal tissue on the injected hemisphere
revealed accumulations of WT a-syn indicative of
dystrophic fibers. In contrast, the D2-11 variant was
homogenously distributed within axonal fibers with an
overall normal morphology (Fig. 7g).
Altogether, these results confirm with two additional
forms of the protein that the a-syn variants able to associate
with biological membranes (WT and A53T) are more
prone to cause motor deficits. In contrast, the D2-11 a-syn
mutant with reduced affinity for membranes fails to impair
forepaw motor activity, and produces less severe degen-
erative effects in nigral neurons.
Discussion
Here, we report a motor behavioral phenotype specifically
induced by the overexpression of a-syn in rat nigral neu-
rons. Unilateral expression of human a-syn primarily leads
to an asymmetry in spontaneous motor activity and to a
mild rotational behavior in response to apomorphine. This
motor phenotype is due to reduced dopamine release in the
striatum, to an extent that clearly exceeds the measured
loss of neurons, axons, and striatal dopamine. Seeking for
ultrastructural correlates of this functional defect, we find a
40% loss of presynaptic vesicles in striatal dopaminergic
terminals expressing a-syn. Therefore, overabundance of
a-syn causes both a presynaptic deficit in vesicle genesis
and/or recycling and early axonal degeneration that lead to
reduced dopamine release and explain the detrimental
effects on motor behavior.
In the experimental conditions employed here which
lead only to mild degeneration, neuronal loss would
account only for a 20–30% decrease in the striatal capacity
for dopamine release, when compared to the intact hemi-
sphere. Total dopamine content in the striatum is reduced
to a similar extent. Although there is no significant
decrease in dopamine metabolite content, we did not
measure any clear change in the rate of dopamine metab-
olism, which would have been indicated by an increased
DOPAC/dopamine ratio. Therefore, the lack of dopamine
is primarily due to axonal fiber loss. This result contrasts to
some extent with previous reports indicating increased
dopamine metabolism induced by the A53T a-syn mutant,
when compared to a GFP-expressing control vector [12].
Experiments based on various degrees of intoxication with
the selective toxin 6–OHDA indicate that a low level of
Fig. 7 Using an AAV vectors for enhanced expression, both the WT
and A53T forms of a-syn lead to motor asymmetry, in contrast to the
membrane-binding deficient D2-11 mutant. a Wild type and A53T
a-syn lead to spontaneous motor asymmetry as measured in the
cylinder test, significantly different from the D2-11 a-syn form. Two-
way repeated measure ANOVA with Newman–Keuls post hoc test:
group 9 time, F(4,54) = 10.25, WT a-syn: n = 16, A53T: n = 7,
D2-11: n = 8; *p \ 0.05 and ***p \ 0.001 versus the other groups.
b Wild type and A53T a-syn progressively induce contraversive
apomorphine-induced rotations, in contrast to the D2-11 a-syn form.
Two-way repeated measure ANOVA with Newman–Keuls post hoc
test: group 9 time, F(4,56) = 2.58, #p \ 0.05 versus A53T and
p = 0.1 versus a-syn WT. c, d Representative photomicrographs
of TH-immunostained nigral (c) and striatal sections (d) for each
animal group. Asterisk indicates the injected hemisphere. e Loss of
TH-positive neurons in the SNpc and f loss of TH immunoreactivity
(optical density) in the striatum as compared to the non-injected
hemisphere. One-way ANOVA with Newman–Keuls post hoc:
***p \ 0.001 and #p = 0.07 versus the other groups. g Photomicro-
graphs of striatal tissue immunostained for human a-syn. Note the
presence of dystrophic axons only in the a-syn WT animals
(arrowheads). Scale bar: 20 lm
c
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nigrostriatal damage, such as the one observed in our
model system, is unlikely to produce measurable motor
asymmetries [27]. Indeed, we do not observe any clear
rotational behavior in response to amphetamine, the effect
of which mainly relates to an asymmetric dopamine con-
tent in the striatum. Even more so, animals injected with
the WT a-syn vector tend to display contraversive
rotational behavior, suggesting that WT a-syn may have
subtle effects modulating amphetamine-induced dopamine
release. Although such a contraversive rotational response
to amphetamine has previously been documented and
possibly associated with a-syn-mediated inhibition of
phospholipase D2 activity [20], further exploration will
be needed to determine its exact cause. Nevertheless,
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amperometric recordings reveal an overall *50% reduc-
tion in depolarization-induced dopamine release following
WT a-syn overexpression. Therefore, it is safe to assume
that spontaneous motor asymmetry in the cylinder test is
largely caused by impaired dopamine release, which affects
dopamine signaling despite only a minor loss of total
striatal dopamine content. Similarly, the progressive
development of apomorphine-induced rotations could
reflect dopamine receptor hypersensitization in response to
the reduced amount of dopamine release.
The clear phenotypic difference between the WT and
A30P forms highlights the importance of functional deficits
induced by a-syn in the surviving nigral neurons. Indeed,
despite a better preservation of the dopaminergic markers
with the A30P mutant, both forms of a-syn induce a similar
loss in striatal dopamine content (Fig. 1d). The clear dif-
ference in motor behavior between the two forms of a-syn
therefore offers an opportunity to explore the cellular
changes that closely correlate with this effect. These two
forms of a-syn differentially affect both depolarization-
evoked dopamine release and presynaptic vesicle density.
For the A30P mutant, these measures remain strikingly
similar to the control non-injected side, highlighting the
lack of effect on intracellular vesicle dynamics for this
form of a-syn.
The pathogenic A30P mutation reduces the affinity of
a-syn for biological membranes, similar to the rational
D2-11 deletion which destabilizes N-terminal a-helix
conformation [53]. Reduced affinity for membranes may
impact on both the normal role and pathophysiological
effects of the protein [3]. The absence of motor effects
upon overexpression of the D2-11 and A30P mutants
underlines the role that membrane association of a-syn
may have in dopamine neurotransmission. It is however
possible that another biochemical property, such as the
propensity to aggregate, further contributes to the observed
differences between these forms of a-syn. The lack of
effect for the A30P mutant has been reported in several
model systems. Notably, the A30P mutant fails to impair
the growth of yeast cells [41], and does not produce the
same effects as WT or A53T a-syn in the maintenance and
function of the neuronal presynaptic compartment [10, 39].
In the present study, we conclude that the overabundance
of WT a-syn, in contrast to the A30P and D2-11 mutants,
interferes with the functioning of dopaminergic axons
leading to reduced dopamine release and motor symptoms.
With respect to its pathogenic role, the A30P mutation
may act in a different manner and lead to inheritable PD
cases via the gain of an alternative toxic function. Previous
reports found some negative effects of the A30P a-syn
mutant on dopamine release. In the mouse nigrostriatal
system, A30P a-syn was found to impact on vesicular
release following high frequency stimulation to exhaust the
readily releasable pool of striatal dopamine [56]. A second
study using a-syn-overexpressing chromaffin cells found a
decrease in the releasable pool of catecholamine-contain-
ing vesicles [34]. Overall, although all forms of a-syn may
interfere at various levels with vesicular neurotransmitter
release, our results suggest that membrane-binding forms
correlate with more dramatic impairments of dopamine
release in the rat nigrostriatal system.
In our experimental conditions, which intentionally
lead to minor degeneration of the nigrostriatal system, the
A30P mutant associated with an autosomal dominant
form of PD is found to be less toxic than WT a-syn. It is
however clearly possible that the A30P mutant would
display neuronal toxicity with higher vector dose and/or
enhanced expression systems. Indeed, although the rare
patients carrying the A30P mutation have a later age of
disease onset as compared to patients with the A53T
mutation or a-syn triplication, they develop nigral
degeneration [32, 46]. While our results parallel some
observations made in the yeast model, they contrast with
the previously observed A30P toxicity obtained with ni-
gral injections of lentiviral vectors [35, 55] and with one
study using an AAV vector [30]. However, a recent study
using an AAV2 vector similar to our model system also
shows less toxicity with the A30P mutant than with WT
a-syn [52]. To our opinion, these discrepancies highlight
the critical importance of parameters that include (1) the
model organism, (2) the viral system employed to induce
a-syn overexpression, and (3) the resulting levels and
kinetics of a-syn overexpression. A30P a-syn toxicity
using AAV vector was also reported following a 1-year
time course using a cba promoter that is likely to generate
higher expression levels than the pgk-1 promoter used in
the present study [30]. There was no direct comparison
with WT a-syn and no behavioral phenotype was
observed despite a [50% loss of nigral neurons. On the
other hand, lentiviral and AAV preparations may differ-
entially influence the context and conditions leading to
a-syn toxicity. Inherent vector properties determine the
level of transgene expression and the time needed for
the vector to achieve maximal expression. Although the
pathologic response has been carefully addressed as a
function of a-syn levels in the yeast model [41], it is
technically more difficult to precisely control a-syn levels
in nigral neurons using viral vector injections. We mea-
sured in brain tissue a two- to three-fold increase in levels
of total a-syn, consistent with previous studies using
similar AAV vectors [4, 21]. However, it is likely that the
level of overexpression achieved in individual neurons is
higher, considering the contribution of non-transduced
cells in the protein extract. Furthermore, the preparations
of AAV and lentiviral vectors notably differ in the degree
of purification achieved. The potential presence of
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cellular contaminants in concentrated lentiviral suspen-
sions may provoke local inflammatory reactions
contributing to the induced phenotype. In conclusion, the
various models currently available may reveal different
aspects of the a-syn pathology contributing to nigral
degeneration and/or motor deficits.
While the A30P and D2-11 forms fail to impair motor
behavior and tend to display less toxicity than WT human
a-syn in the nigrostriatal system, it remains unclear whe-
ther any mechanism may link these effects. In the yeast
model, the impact of a-syn on cellular functions relates to
its expression level. While low levels of a-syn primarily
impair vesicular trafficking, higher levels lead to mito-
chondrial toxicity [51]. A similar gradation may exist in
nigral neurons, with effects on vesicular dopamine release
preceding overt degeneration. Therefore, it is possible that
higher expression levels of the A30P mutant and/or pro-
longed expression will produce pathological effects similar
to WT a-syn in the AAV model system [30].
We observed a reduction of both vesicle density and the
number of synapses in dopaminergic axons, providing a
cellular correlate for the deregulation of nigrostriatal
dopamine transmission upon WT a-syn overexpression.
A recent study explored the presynaptic effects of a-syn
overexpression using mouse glutamatergic synapses,
reporting a reduced size of the recycling pool of vesicles
and impaired clustering of vesicles after exocytosis [39].
While a smaller number of vesicles were found near the
release zone, total vesicle numbers remained unchanged.
In the nigral dopaminergic neurons which are primarily
involved in PD motor symptoms, we observed a marked
reduction in overall vesicle density, suggesting a deficiency
in vesicle formation or turnover. Indeed, WT but not A30P
a-syn disrupts vesicle trafficking between the endoplasmic
reticulum and the Golgi apparatus [19], which might con-
tribute to a reduction in the pool of vesicles present at the
level of the nerve terminals.
It will be important to determine in more details how the
observed lack of presynaptic vesicles relates to dopamine
release. Indeed, a-syn specifically regulates either reserve
or recycling pools of vesicles in glutamatergic synapses [8,
39]. It is unclear how this is linked to the overall reduction
in vesicle density found in dopamine striatal axons. The
lack of vesicles also suggests a possible re-distribution
between vesicular and cytosolic dopamine [38]. It will be
important to determine if a-syn leads to elevated levels of
dopamine in the cytosol in vivo. Indeed, cytosolic dopa-
mine is prone to auto-oxidation, leading to oxidative stress
[36] and possibly mitochondrial degeneration, which may
contribute to a-syn-induced neurodegeneration. Interest-
ingly, we observed a drastic increase in autophagocytic
structures often associated with degenerating mitochondria
in nigrostriatal axons overexpressing WT a-syn.
Overall, mild levels of human a-syn in rat nigral neu-
rons lead to a deficiency in dopamine release preceding
outright neuron loss. In patients with a-syn gene multipli-
cations, as well as in sporadic forms of PD, the onset of
motor symptoms may be due in part to functional pertur-
bations that affect the release and storage of dopamine, and
possibly contribute to the degeneration of the selectively
vulnerable nigrostriatal system.
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